Here, we have established multiple mutant KRAS-driven cancer cell lines with acquired resistance to the purine-scaffold HSP90 inhibitor PU-H71 to prospectively identify mechanisms through which HSP90-dependent cancer cells evade pharmacologic HSP90 blockade. This evidence concerns the gene KRAS and cancer.